BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is ...

Exhibit 99.1 AMEDISYS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (April 24, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the threemonth period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 ◦ Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023. ◦ Net incom ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

A month has gone by since the last earnings report for Amedisys (AMED) . Shares have lost about 2.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Amedisys due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Amedisys Q4 Earnings Miss Estimates, Margins RiseAmedisys, ...

One stock that might be an intriguing choice for investors right now is Amedisys, Inc. (AMED) . This is because this security in the Medical - Outpatient and Home Healthcare space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and est ...

Core Insights - Amedisys reported revenue of $570.79 million for Q4 2023, a year-over-year increase of 1.6% and an EPS of $0.94, down from $1.16 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $564.85 million by 1.05%, while the EPS fell short of the consensus estimate of $1.04 by 9.62% [1] Revenue Breakdown - Net Service Revenue from Home Health was $358.90 million, surpassing the average estimate of $356.95 million, reflecting a year-over-year increase of 4.8% [2] - Net Service Revenue from High Acuity Care was $5.90 million, matching the average estimate of $4.90 million, with no year-over-year change [2] - Net Service Revenue from Hospice reached $206 million, exceeding the average estimate of $200.35 million, representing a year-over-year increase of 4.3% [2] Stock Performance - Amedisys shares have returned -1.1% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3% [2] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [2]

Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.62%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.08 per share when it actually produced earnings of $0.98, delivering a surprise of -9.26%.Over the ...

| --- | --- | |-------|-------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. (E ...

Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 21, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 ◦ Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was diveste ...